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Topical administration of psychotropic medications in
pluronic lecithin organogel (PLO) to treat patients with
dementia: a retrospective observational study
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ABSTRACT
O bjective: Treatment of mood and behavioral symptoms in geriatric patients with
advanced dementia may be impeded by poor compliance with oral medications.
Pluronic lecithin organogel (PLO) is a compounding substrate that can be used for the
topical administration of psychotropic medications.
Methods: Charts of patients treated with psychotropic medications compounded with
PLO cream were reviewed for treatment outcomes. All patients were treated by a
nursing home outreach service.
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Results : Records from twenty-four patients, mean age 86.8 + 5.9, were reviewed.
Common psychiatric symptoms included agitation, aggressive behavior, and
depression. Medications most commonly administered as a PLO cream included
quetiapine and venlafaxine. All patients had mild to marked improvement in psychiatric
symptoms.
Conclusions: Pluronic lecithin organogel (PLO) may be an effective option for the topical
administration of psychiatric medications in geriatric patients with dementia who are
not compliant with oral medications.
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INTRODUCTION
More than eighty percent of geriatric patients with
dementia develop mood and behavioral symptoms
during the course of their illness.1,2 Psychotropic
medications can effectively treat these symptoms.
However, patients with dementia may not comply
with oral medications due to behavioral issues,
paranoia or swallowing difficulty. Alternative routes
for administering medications are needed to increase
compliance and improve outcomes.
During the past 20 years, several drugs have been
formulated for topical administration including
scopolamine, nitroglycerin, nicotine, rivastigmine and
fentanyl. These drugs are combined with permeation
enhancers to increase passive transdermal diffusion
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through the skin into the circulation. Currently,
selegiline and methylphenidate are the only
psychotropic medications available in a transdermal
formulation.
Pluronic lecithin organogel (PLO) is a synthetic
compound developed in the 1990s as a transdermal
drug delivery substrate.3,4,5 When combined with
a therapeutic agent, PLO forms drug micelles in a
thermodynamically stable cream. The FDA permits
the mixing and physical modification (compounding)
of medications by a pharmacist upon receipt of a
prescription from a licensed practitioner to meet the
unique needs of an individually identified patient.
Compounding psychotropic medications with PLO
can offer new treatment options for geriatric patients
with dementia.
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PLO has three major components; lecithin, isopropyl
palmitate, and poloxamer (Pluronic). All three
components act as skin permeation enhancers.
Lecithin is a naturally occurring fatty substance
which is a surfactant and acts as an emulsifier.
Isopropyl palmitate is a palm oil based moisturizer
and thickening agent. Both lecithin and isopropyl
palmitate are commonly used in various topical
products and can effectively dissolve lipophilic drugs.
Poloxamer is a copolymer of polyoxypropylene and
polyoxyethylene, and is FDA approved for human
use. The structure of poloxamer promotes the
formation of drug micelles when mixed with lecithin
and isopropyl palmitate. A thermodynamically stable
cream is formed when the three components are
mixed together.
At this time, there are very few studies evaluating
the clinical effectiveness of medications applied
topically using PLO. Two recent prospective trials
reported improvement in nausea and vomiting
induced by chemotherapy when patients were
treated with lorazepam, diphenhydramine and
haloperidol compounded with PLO.6,7 These trials
concluded that administering medications topically
via PLO reduces gastrointestional side effects and
improves patient compliance, without significant
skin irritation. However, in a study evaluating
the plasma concentrations of lorazepam (2mg),
diphenhydramine (25mg) and haloperidol (2mg)
administered topically using PLO; lorazepam and
haloperidol were not detectable, and only five of
the 10 subjects had detectable plasma levels of
diphenhydramine.8
To our knowledge, there are no studies assessing
the effectiveness of topically applied psychotropic
medications compounded with PLO cream for the
treatment of psychiatric symptoms. For a number
of years, we have used PLO creams to administer
psychiatric medications in elderly patients who are
unable or unwilling to take oral medications. For this
study, we reviewed the records of 24 geriatric patients
who were treated with psychiatric medications
applied topically using PLO cream. All patients had
advanced dementia with psychiatric symptoms that
significantly impacted the patient’s quality of life or
caretakers’ ability to provide basic care, and were
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unwilling or unable to take oral medications.
METHODS
A retrospective chart review was carried out by
the authors on all geriatric psychiatry patients
treated with topical psychotropic medications
using PLO. A structured data collection form was
used to collect data including age, gender, living
situation, medications, medical and psychiatric
diagnoses, psychiatric/behavioral symptoms and
the Mini Mental State Exam score (MMSE).9 The
authors accessed response to therapy by reviewing
the medical record, which contained the nursing
staff and physician’s clinical assessment of patients.
Response was rated on a 4 point scale; (1) no
improvement, (2) mild improvement, (3) moderate
improvement, or (4) marked improvement.
Statistical analysis was carried out using SPSS for
descriptive variables.
RESULTS
Twenty-four geriatric psychiatry records were
reviewed. Demographic and clinical variables are
shown in Table 1. All patients had severe dementia
and resided in skilled nursing facilities. Psychiatric
diagnoses included major depression (n = 17,
70.8%) and mood disorder secondary to general
medical condition (n = 3, 12.5%). Medical conditions
included hypertension (n = 17, 70.8%), stroke (n
= 12, 50%), coronary artery disease (n = 8, 33.3%),
hyperlipidemia (n = 6, 25%), diabetes (n = 2, 8.3%),
hypothyroidism (n = 5, 20.8%), seizure disorder (n =
3, 12.5%) and osteoarthritis (n = 5, 20.8%).
Reasons for starting PLO psychiatric medications
included: physical aggressiveness and agitation (n
= 19, 79.2%), depressive symptoms (n = 15, 62.5%),
decreased appetite (n = 10, 41.7%), insomnia (n = 5,
20.8%), and psychotic symptoms (n = 2, 8.3%). Six
different psychiatric medications were used in PLO
formulation: quetiapine, venlafaxine, trazodone,
buspirone, escitalopram and lorazepam.
Quetiapine was used in eighteen patients at an
individual dosage range from 12.5 mg to 100 mg
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Before starting PLO medication, all
patients had been non-compliant with
or unable to take oral medications.
PLO compounded medications were
applied to the inner aspect of the
forearm in all patients except one who
had PLO cream applied to his back due
to physical aggressiveness. No side
effects were reported in any of the
patients.

TABLE 1. Demographics, Clinical Characteristics and
Outcomes

(mean = 57.6 ± 34.9), given one to four times a day,
for a total daily dose of 25 mg to 300 mg (mean =
136.1 ± 97.5). Mean duration of treatment was 5.3 ±
4.6 months.
Venlafaxine was used in fifteen patients at an
individual dose range of 37.5 mg to 100 mg (mean
= 66.6 ± 17.6). Venlafaxine was administered twice
a day in fourteen patients and three times a day in
one patient. Total daily dose of venlafaxine ranged
between 75 mg to 200 mg (mean= 135.7 ± 37.9), and
mean duration of treatment was 5.5 ± 4.4 months at
time of review. Nine patients were treated with both
quetiapine PLO cream and venlafaxine PLO cream.
Five patients received trazodone PLO cream at a
dose of 50 mg to 100 mg at bedtime for insomnia
(mean= 70 ± 27.4). The mean duration of treatment
with trazodone was 3 + 1.4 months at time of chart
review. Four patients who were treated with topical
trazodone also received topical quetiapine and two
received topical venlafaxine. Two patients received
topical buspirone at a dose of 5-10 mg (mean = 7.5 ±
3.5). Buspirone was administered three times a day
with a total daily dose between 15-30 mg (mean=
22.5 ± 10.6). One hospice patient received 1mg
lorazepam PLO cream four times a day. One patient
received 20mg escitalopram PLO cream daily for 11
months.
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All patients benefited from PLO
medications as shown in Table 1.
Improvement in symptoms were as
follows: 12 patients (50%) were more
compliant with oral medications, 13
of 19 (68.4%) patients with severe
agitation improved, 11 of 15 (73.3%)
patients with depressive mood improved, 6 of 10
(60%) patients had improved appetite, and 2 of 5
(40%) had improvement in sleep. Two patients who
received PLO for psychotic symptoms were rated as
moderately improved.
The following two clinical vignettes illustrate the use
of psychotropic PLO cream.
CASE VIGNETTES
Subject 1
Ms. A was a 78 year-old woman with vascular
dementia, who was referred for evaluation of
depression, behavioral disturbance and poor
appetite. Ms. A stated that her mood was “not
too good”, and she was irritable, anxious and
uncooperative with care by nursing home staff. MiniMental State Examination was 7/30. She was treated
with oral venlafaxine extended-release 75mg daily
with improvement of appetite and mood, however
she continued to be anxious and was uncooperative.
Buspirone 5mg bid was used with good results.
Over the following year, her cognitive impairment
progressed and she became uncooperative with
all oral medication. Her depressive and behavioral
symptoms returned. She was started on venlafaxine
50mg PLO topical cream bid and buspirone 10mg
PLO topical cream bid. Four weeks after starting PLO
cream, the nursing home staff reported significant
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improvement in her depressive and behavioral
symptoms.
Subject 2
Mr. B was an 84 year-old man diagnosed with mixed
type (Alzheimer’s and Vascular) dementia, who
was referred for evaluation of insomnia and severe
aggression toward staff and other residents. MMSE
was 0/30. Eventually, the patient was treated with
a medication regimen of quetiapine 100mg bid,
valaproic acid syrup 750mg bid and trazodone 50mg
qhs, with marked improvement in his behavior.
However after 2 years, he became uncooperative
with oral medications and experienced recurrence
of aggression. Strategies to improve compliance
were unsuccessful and oral medications were
discontinued. PLO quetiapine cream 100mg bid and
trazodone 50mg PLO cream qpm were begun. He
was compliant with PLO medications and within two
months his behavior markedly improved.
DISCUSSION
Patients with advanced dementia frequently do not
comply with oral medications due to behavioral
issues, paranoid thoughts about treatment
intentions, or difficulty with swallowing pills.
Transdermal administration of medications in this
patient population offer many advantages including
improved tolerability, ease of administration, and
steady continuous delivery rate. Pluronic lecithin
organogel (PLO) is a synthetic compound that
has been developed as a substrate for the topical
administration of therapeutic agents.
A limited number of studies have evaluated the
bioavailability of medications administered topically
when combined with PLO cream. Finding from
these studies typically reveal low or undetectable
serum levels of medications, however, the doses
of medications used in these studies may be too
low for adequate transdermal absorption.10,11 For
example, Glisson et al. administered promethazine
50mg compounded with PLO in 15 subjects; blood
samples were collected over a 6 hour period.12
Only 65% of the blood samples had measurable
serum concentrations of promethazine, and only
39.2% of these samples contained quantifiable
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concentrations of the drug equal to or greater than
1 ng/mL. Interestingly, eleven of the fifteen subjects
in this study experienced drowsiness. In another
study, methadone (dose range 10mg to 45mg)
compounded with PLO was administered topically
to ten subjects.13 Only one subject who received
the 45mg dose of methadone achieved measurable
serum levels. These studies suggest that when
compounding a medication with PLO for topical
application, a higher dose of medication is needed in
order to obtain serum levels similar to that observed
with oral administration. The reduced absorption
of medications when administered transdermally
is reflected by the fact that currently available
transdermal therapeutic patches are formulated with
significantly higher doses of the therapeutic agent
when compared to oral formulations. For example,
methylphenidate patch contain between 27.5mg to
82.5mg per patch, selegiline patch contain between
20mg to 40mg per patch, and rivastigmine patch
contains 9mg to 27mg per patch.
In our case series, a variety of psychotropic
medications were administered topically using
PLO cream in patients unwilling or unable to take
oral medications. Based on our retrospective chart
reviews, all patients demonstrated some clinical
improvement in their psychiatric symptoms. This
case series was limited to geriatric patients with
dementia; however other groups of patients
with psychiatric disorders may benefit from PLO
compounded medications.
Our study has a number of limitations, including
the retrospective observational design and
small sample size. Because of the observational
design, we cannot rule out the possibility that
the observed improvements were due to placebo
effect of PLO cream application. Also, we assessed
the effectiveness of several different psychotropic
medications applied topically with PLO cream, which
limits the conclusions that can be draw concerning
the effectiveness of any specific agent. However,
the goal of this study was to demonstrate that
compounding medications with PLO for topical
application may offer an effective alternative for
treatment of complex geriatric patients. There may
be concerns about the patient population in this
study; however clinical trials have not consistently
revealed any significant differences in transdermal
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absorption of medications when comparing young
and old patients.14
In conclusion, compounding psychotropic
medications with pluronic lecithin organogel (PLO)
provides the opportunity for topical application
of a wide range of medications. However, more
research is needed to determine the absorption
rates and bioavailability of different medications
when administered with PLO cream. Although our
series was limited to the use of six medications, we
expect that other psychiatric medications could be
effectively administered as a PLO creams, thereby
expanding the treatment options for geriatric
patients, as well as psychiatric patients in general.
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